ES2524894T3 - Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe - Google Patents

Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe Download PDF

Info

Publication number
ES2524894T3
ES2524894T3 ES11781731.2T ES11781731T ES2524894T3 ES 2524894 T3 ES2524894 T3 ES 2524894T3 ES 11781731 T ES11781731 T ES 11781731T ES 2524894 T3 ES2524894 T3 ES 2524894T3
Authority
ES
Spain
Prior art keywords
influenza virus
permanent human
cell line
human amniocyte
virus production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11781731.2T
Other languages
English (en)
Inventor
Gudrun Schiedner
Udo Reichl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cevec Pharmaceuticals GmbH
Original Assignee
Cevec Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals GmbH filed Critical Cevec Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2524894T3 publication Critical patent/ES2524894T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un procedimiento de producción de una vacuna a base de virus de la gripe, que comprende: a) infectar un amniocito humano permanente con un virus de la gripe; b) cultivar el amniocito humano permanente; c) expresar el virus de la gripe; y d) aislar el virus de la gripe del medio, en el que el amniocito humano permanente expresa los productos génicos adenovirales E1A y E1B.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15

Claims (1)

  1. imagen1
ES11781731.2T 2010-08-16 2011-08-16 Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe Active ES2524894T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102010037008 2010-08-16
DE102010037008 2010-08-16
DE102011050353 2011-05-13
DE102011050353 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (1)

Publication Number Publication Date
ES2524894T3 true ES2524894T3 (es) 2014-12-15

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11781731.2T Active ES2524894T3 (es) 2010-08-16 2011-08-16 Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe

Country Status (19)

Country Link
US (1) US20130344569A1 (es)
EP (1) EP2606128B1 (es)
JP (1) JP5928843B2 (es)
KR (1) KR101780257B1 (es)
CN (1) CN103168100B (es)
AU (1) AU2011307655B2 (es)
BR (1) BR112013003766B1 (es)
CA (1) CA2808453C (es)
DE (1) DE112011102737A5 (es)
DK (1) DK2606128T3 (es)
ES (1) ES2524894T3 (es)
IL (1) IL224728A (es)
MX (1) MX337687B (es)
PL (1) PL2606128T3 (es)
PT (1) PT2606128E (es)
RU (1) RU2565546C2 (es)
SG (1) SG187863A1 (es)
TW (1) TW201211257A (es)
WO (1) WO2012041311A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1831353B1 (en) * 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
EP1945778B1 (en) * 2005-10-17 2012-12-26 MedImmune, LLC Methods of increasing influenza virus replication
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2008105931A2 (en) * 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Also Published As

Publication number Publication date
CN103168100A (zh) 2013-06-19
PL2606128T3 (pl) 2015-02-27
BR112013003766B1 (pt) 2021-08-24
PT2606128E (pt) 2014-12-09
MX2013001772A (es) 2013-06-03
CA2808453C (en) 2020-05-05
JP5928843B2 (ja) 2016-06-01
SG187863A1 (en) 2013-03-28
EP2606128A1 (de) 2013-06-26
AU2011307655B2 (en) 2015-12-17
MX337687B (es) 2016-03-15
KR101780257B1 (ko) 2017-09-21
RU2013110786A (ru) 2014-09-27
EP2606128B1 (de) 2014-09-10
US20130344569A1 (en) 2013-12-26
CA2808453A1 (en) 2012-04-05
BR112013003766A2 (pt) 2016-05-31
TW201211257A (en) 2012-03-16
WO2012041311A1 (de) 2012-04-05
DE112011102737A5 (de) 2013-06-06
JP2013537543A (ja) 2013-10-03
IL224728A (en) 2016-05-31
DK2606128T3 (en) 2014-12-01
AU2011307655A1 (en) 2013-03-21
RU2565546C2 (ru) 2015-10-20
KR20130097191A (ko) 2013-09-02
CN103168100B (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
EA201300915A1 (ru) Новый европейский штамм prrsv
CR20150170A (es) Vacunas de inmersión subunidad para peces
ES2613400T3 (es) Método para mejorar la fagocitosis de células que exponen fosfatidilserina
JP2011004745A5 (es)
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
AR101468A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
ES2524894T3 (es) Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe
ES2565198T3 (es) Metapneumovirus aviar en oncólisis
Дроздова et al. The Keys. English Grammar
ES2560329T3 (es) Procedimiento de transformación de iota-carragenano en alfa-carragenano por medio de una clase novedosa de 4S-iota-carragenano sulfatasa
RU2011140186A (ru) Галогенсодержащие ароматические полиэфиры
CU24328B1 (es) Método para la generación de una cadena rotavirus humana atenuada rv3 en células vero
ES2478692A1 (es) Formulaciones líquidas de carbocisteína de propiedades mejoradas
WO2015071763A3 (en) Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
RU2010121552A (ru) Штамм bifidobacterium longum гв-9, используемый для получения бифидосодержащей продукции
RU2010121553A (ru) Штамм bifidobacterium bifidum 74-23, используемый для получения бифидосодержащей продукции
RU2010119250A (ru) Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции
RU2011116802A (ru) 1-(1-адамантил)-4-нитрозопиразолы
RU2010119255A (ru) Штамм bifidobacterium adolescentis 79-82, используемый для получения бифидосодержащей продукции
TH121338S (th) เครื่องดูดฝุ่น
RU2010119257A (ru) Штамм bifidobacterium adolescentis 79-66, используемый для получения бифидосодержащей продукции
RU2010119242A (ru) Штамм bifidobacterium longum го-10, используемый для получения бифидосодержащей продукции
RU2009149126A (ru) Диметил 4-фенилэтиламино-2-(4-метоксифенил)-6-гидрокси-6-метил-3-циклогексен-1,3-дикарбоксилат, проявляющий противовоспалительное действие
RU2010121557A (ru) Штамм bifidobacterium adolescentis вл-1, используемый для получения бифидосодержащей продукции